Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies
Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.
You may also be interested in...
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.
Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.
Faced with the prospect of a compulsory license in Malaysia, Gilead has reviewed its generic licensing agreements to grant access to low-cost versions of its HIV and hepatitis C drugs in the country and three other middle-income nations.